Reamberin® solution for infusion, 1.5 %
Open Multicenter Prospective Observational Trial of the Efficacy and Safety of Use of Drug Product Reamberin® Solution for Infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07066540/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: 1–6 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 300 чел. во всех странах исследования.
- Центров в реестре: 7 в 6 городах. Список — ниже на странице.
- Плановое окончание — 12.2026.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 6
Критерии включения
- Children of both sexes at the age of 1 to 6 years old inclusive;
- Diagnosis "Viral and other specified intestinal infections" (code according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision(ICD-10): A08),
- Clinical signs of endogenous intoxication (nausea, vomiting, hyperthermia, headache, muscle pain, asthenia, adynamia, etc.);
- Indication for parenteral rehydratation (infusion therapy);
- Decision of a physician on prescribing drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") in the daily dose of 10 mL/kg and normal saline NaCl/5 % or 10 % solution of glucose or normal saline NaCl/Ringer's solution/5 % or 10 % solution of glucose;
- To confirm the diagnosis by laboratory tests, biological material was taken;
- Informed Consent Form on Participation in the Observational Program signed and dated by a parent/legal representative of the patient.
Критерии невключения
- Individual intolerance or known hypersensitivity to sodium meglumine, sodium succinate, and/or normal saline (NaCl), solution of glucose, Ringer's solution or excipients of drug product Reamberin® based on data of medical history;
- Contraindications to prescription of drug product Reamberin®;
- Necessity in surgical interventions during the observational program;
- Patients previously enrolled in this trial but discontinued participation due to any any reason;
- Administration of antibiotics or succinate-containing drug products (Cytoflavin, Mexidol, etc.) and solutions containing malate;
- Other conditions that, according to the Investigator, prevent enrollment of a patient into the observational trial or can result in premature discontinuation of the observational trial by the patient
Источник: ClinicalTrials.gov, NCT07066540 · запись обновлена в реестре 15 июля 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (6), вторичных — 10
- Proportion of patients in groups who continued to receive infusion therapy 24 hours and 48 hours after the start of the treatment — 24 hours, 48 hours
- Average duration of infusion therapy in groups, expressed in days — Day 10
- Average durations of symptoms of damage of the gastrointestinal tract in groups — Day 10
- Average duration of symptoms of intoxication in groups — Day 10
- Share of patients in groups with moderate form and severe form 48 hours after the start of the treatment — 48 hours
- Average duration of stay of patients in an inpatient healthcare facility — Day 10
Цель исследования
To assess the efficacy and safety of use of drug product Reamberin® solution for infusion, 1.5 % (Scientific Technological Pharmaceutical Firm "POLYSAN") for pathogenetic therapy of viral enteric infection in children aged 1-6 years old in routine clinical practice. Trial population: children of both sexes at the age of 1-6 years old inclusive with viral enteric infection.
Где проходит
7 центров в 6 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07066540 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.